FDA Resumes eIND Approval for Severe-to-Critical COVID-19 Patients Use of Vyrologix™ (leronlimab) Following Full Enrollment in CytoDyn’s Phase 3 Trial
FDA’s decision will enable CytoDyn to respond to ongoing requests for leronlimab until Phase 3 trial data is unblinded VANCOUVER,
Read more